Publications by authors named "Christopher Di Simone"

Claim this Profile
L
Lenvatinib plus Pembrolizumab Following Immune Checkpoint Inhibitor Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Results from Study 111/KEYNOTE-146.
Chung-Han Lee, Amishi Yogesh Shah, Arpit Rao, Matthew H Taylor, Christopher Di Simone

Eur Urol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146.
Vicky Makker, Matthew H Taylor, Carol Aghajanian, Allen L Cohn, Marcia S Brose, Christopher Di Simone

J Immunother Cancer· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
Chung-Han Lee, Amishi Yogesh Shah, Drew Rasco, Arpit Rao, Matthew H Taylor, Christopher Di Simone

Lancet Oncol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma.
David F McDermott, Jae-Lyun Lee, Georg A Bjarnason, James M G Larkin, Rustem A Gafanov, Christopher DiSimone

J Clin Oncol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer.
Vicky Makker, Matthew H Taylor, Carol Aghajanian, Ana Oaknin, James Mier, Christopher DiSimone

J Clin Oncol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.
Vicky Makker, Drew Rasco, Nicholas J Vogelzang, Marcia S Brose, Allen L Cohn, Christopher Di Simone

Lancet Oncol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018).
Sneha Berry, Nicolas Giraldo, Peter Nguyen, Benjamin Green, Haiying Xu, Christopher Di Simone, Christopher Di Simone

J Immunother Cancer· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis